Altimmune Stock Analysis

Altimmune Stock Analysis Notes

About 63.0% of the company shares are held by institutions such as insurance companies. The book value of Altimmune was presently reported as 2.75. The company recorded a loss per share of 1.66. Altimmune last dividend was issued on the 20th of January 2017. The entity had 1:30 split on the 14th of September 2018. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. For more info on Altimmune please contact William Enright at 240 654 1450 or go to https://altimmune.com.

Altimmune Investment Alerts

Altimmune Upcoming and Recent Events

Altimmune Largest EPS Surprises

View All Earnings Estimates

Altimmune Stock Institutional Investors

Note, although Altimmune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Altimmune Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 529.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Altimmune's market, we take the total number of its shares issued and multiply it by Altimmune's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Altimmune Profitablity

Management Efficiency

Altimmune has Return on Asset of (0.25) % which means that on every $100 spent on assets, it lost $0.25. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4663) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.44 in 2024. Total Current Liabilities is likely to gain to about 21.2 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 221.2 M in 2024

Technical Drivers

As of the 24th of April, Altimmune shows the Risk Adjusted Performance of (0.02), standard deviation of 7.35, and Mean Deviation of 5.28. Altimmune technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Altimmune, which can be compared to its peers. Please confirm Altimmune market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Altimmune is priced correctly, providing market reflects its regular price of 7.57 per share. Given that Altimmune has information ratio of (0.05), we suggest you to validate Altimmune's prevailing market performance to make sure the company can sustain itself at a future point.

Altimmune Price Movement Analysis

Altimmune Insider Trading Activities

Altimmune Predictive Daily Indicators

Altimmune Corporate Filings

Altimmune Forecast Models

Altimmune's time-series forecasting models are one of many Altimmune's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Altimmune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Altimmune prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Altimmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Altimmune. By using and applying Altimmune Stock analysis, traders can create a robust methodology for identifying Altimmune entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Altimmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Altimmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Altimmune stock analysis indicators help investors evaluate how Altimmune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Altimmune shares will generate the highest return on investment. By understating and applying Altimmune stock analysis, traders can identify Altimmune position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.

Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.